Year: 2024
Type: article
Abstract: The present review aimed to explore the treatment of metabolic bone diseases using anti-sclerostin antibodies, including Osteoporosis, Osteogenesis Imperfecta, Hypophosphatemia, Paget's disease, Fibrous Dysplasia, Multiple Myeloma, Fluorosis, and McCune-Albright Syndrome.These disorders representing metabolic bone diseases are elaborated in the present work.Literature was searched from publicly available databases including PubMed, Scopus, and the Web of Science.Most studies, showed that bone mineral density rose and the risk of fracture was decreased in individuals after being treated with anti-sclerostin antibodies.However, the possibility that these antibodies may trigger cardiovascular events or venous thromboembolism was mentioned as a reason for alarm.Even though anti-sclerostin antibodies have shown promise in treating metabolic bone disorders, additional study is required to determine whether or not they pose any safety concerns.
Authors: Ourania Trantafili, George I. Lambrou
Institution: National and Kapodistrian University of Athens
Language: English
Subfield: Orthopedics and Sports Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $107
OpenAlex ID: W4404930952